Foley Hoag provided IP due diligence counsel to Genmab A/S
(NASDAQ: GMAB), an international biotech company specializing in
antibody therapeutics for the treatment of cancer and other serious
diseases, on its proposed $8 billion acquisition of Merus N.V., a
clinical-stage biotechnology company.
The proposed acquisition of Merus, with its late-stage breakthrough
therapy asset petosemtamab, will enable Genmab to accelerate its
shift to a wholly owned model and drive sustained growth and
innovation.
The Foley Hoag team was led by Amy Baker Mandragouras and included
Ariana Harris, Erin Foley, Sammi Devenport, Jordan Isaacs,
Kimberlee Hixon, and Carolyn Blake.
Learn more about the transaction here.
PRESS RELEASE
2 October 2025
Foley Hoag Provides IP Due Diligence Counsel To Genmab A/S On Acquisition Of Merus N.V.
Foley Hoag LLP
Contributor
Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.
Foley Hoag provided IP due diligence counsel to Genmab A/S (NASDAQ: GMAB), an international biotech company specializing in antibody therapeutics for the treatment of cancer...